Use of eltrombopag in aplastic anemia in Europe

Autor: Ecsedi, M., Lengline, E., Knol-Bout, C., Bosman, P., Eikema, D.J., Afanasyev, B., Maschan, A., Dreger, P., Halkes, C.J.M., Drexler, B., Cortelezzi, A., Drenou, B., Patriarca, A., Bruno, B., Onofrillo, D., Lanino, E., Pulanic, D., Serventi-Seiwerth, R., Garnier, A., Ljungman, P., Bonifazi, F., Giammarco, S., Tournilhac, O., Pioltelli, P., Rovo, A., Risitano, A.M., Latour, R.P. de, Dufour, C., Passweg, J., EBMT SAA Working Party

Publikováno v: Ecsedi, Matyas; Lengline, Étienne; Knol-Bout, Cora; Bosman, Paul; Eikema, Dirk-Jan; Afanasyev, Boris; Maschan, Alexei; Dreger, Peter; Halkes, Constantijn J M; Drexler, Beatrice; Cortelezzi, Agostino; Drénou, Bernard; Patriarca, Andrea; Bruno, Benedetto; Onofrillo, Daniela; Lanino, Edoardo; Pulanic, Drazen; Serventi-Seiwerth, Ranka; Garnier, Alice; Ljungman, Per; ... (2019). Use of eltrombopag in aplastic anemia in Europe. Annals of hematology, 98(6), pp. 1341-1350. Springer-Verlag 10.1007/s00277-019-03652-8
Annals of Hematology
Annals of Hematology, Springer Verlag, 2019, 98 (6), pp.1341-1350. ⟨10.1007/s00277-019-03652-8⟩
Annals of Hematology, 98(6), 1341-1350. SPRINGER

Eltrombopag (ELT), an oral thrombopoietin receptor agonist, has recently emerged as a promising new drug for the treatment of aplastic anemia (AA). How ELT is used outside of clinical trials in the real-world setting and results of this treatment are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31aa821628e23ecccb37ba20970a88ab
https://boris.unibe.ch/133197/1/s00277-019-03652-8.pdf

Europe-wide survey on the use of thrombopoietin agonists for the treatment of aplastic anemia

Autor: Ecsedi, M., Lengline, E., Knol-Bout, C., Bosman, P., Afanasyev, B., Maschan, A., Dreger, P., Halkes, S., Drexler, B., Cortelezzi, A., Drenou, B., Gaidano, G., Bruno, B., Onofrillo, D., Lanino, E., Pulanic, D., Serventi-Seiwerth, R., Peterlin, P., Ljungman, P., Bonifazi, F., Sica, S., Tournilhac, O., Pioltelli, P., Tour, R.P. de la, Dufour, C., Passweg, J.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ef89f3cd33bdae53c5b0ebda70e4e059
https://hdl.handle.net/1887/122842

Aloimunizacije kod pacijenata liječenih transplantacijom alogenih krvotvornih matičnih stanica

Autor: Raos M, Bojanic I, Serventi Seiwerth R, Golubic Cepulic B

određen stupanj nepodudarnosti u eritrocitnim antigenima. Velika, mala i obostrana nepodudarnost u ABO sustavu mogu u posttrasplantacijskom periodu uzrokovati akutnu hemolizu ili odgođen oporavak eritropoeze. Aloprotutijela „non anti-A/B“ mogu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::acca99951a55dd8e63a1bcd7f85559fd
https://www.bib.irb.hr/1077847

E10 Stem cell transplantation for multiple myeloma in Croatia: evaluation of the efficacy of double autologous stem cell transplantation

Autor: Nemet, D., Sertić, D., Mrsić, M., Bojanić, I., Batinić, D., Duraković, N., Golubić-Ćepulić, B., Serventi-Seiwerth, R., Radman, I., Aurer, I., Zupančić-Šalek, S., Labar, B.

Publikováno v: In Leukemia Research 2007 31 Supplement 2:S20-S21

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.